→ PhRMA CEO Steve Ubl enjoys holding up Turing’s Martin Shkreli as an example of the kind of “bad actors” that are giving pharma companies a bad name. The Boston Business Journal noted that Ubl singled out Shkreli in a Q&A with reporters. But what about Marathon CEO and PhRMA board member Jeff Aronin, who finds himself at the center of a tempest over the approval of deflazacort? STAT notes: “Ubl wouldn’t say what kind of companies might get the boot from PhRMA once the membership criteria are revised. But he said the revision process ‘should take weeks not months.’ He also confirmed that while Marathon is still a PhRMA member, it’s possible that after the review it might not be.”
→ The UK’s Discuva says it has extended its collaboration with Roche on the discovery and development of new antibiotics to fight drug-resistant bacteria. “This contract amendment enables the programmes to benefit from the exceptional input of both parties and move the programmes more efficiently towards patients,” stated Dr David Williams, CEO of Discuva. “We are passionately committed to establishing a succession of novel antibiotics to meet the challenge that the growing threat of antimicrobial resistance represents.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,500+ biopharma pros who read Endpoints News by email every day.Free Subscription